Caxton Associates LP bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) in the second quarter, HoldingsChannel.com reports. The fund bought 202,157 shares of the biotechnology company’s stock, valued at approximately $708,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of HRTX. Victory Capital Management Inc. grew its holdings in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 4,617 shares in the last quarter. Orchard Capital Management LLC grew its holdings in shares of Heron Therapeutics by 4.7% in the fourth quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock valued at $3,814,000 after purchasing an additional 100,603 shares in the last quarter. Diversified Trust Co purchased a new position in shares of Heron Therapeutics in the first quarter valued at $66,000. Commonwealth Equity Services LLC grew its holdings in shares of Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock valued at $938,000 after purchasing an additional 10,122 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Heron Therapeutics in the first quarter valued at $90,000. 80.01% of the stock is owned by hedge funds and other institutional investors.
Heron Therapeutics Stock Up 8.5 %
HRTX stock opened at $2.05 on Friday. Heron Therapeutics, Inc. has a twelve month low of $0.50 and a twelve month high of $3.93. The stock has a market capitalization of $308.84 million, a price-to-earnings ratio of -3.36 and a beta of 1.80. The firm’s fifty day simple moving average is $2.19 and its two-hundred day simple moving average is $2.76.
Analyst Ratings Changes
A number of research analysts recently weighed in on the stock. Rodman & Renshaw started coverage on shares of Heron Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Wednesday.
Get Our Latest Stock Analysis on Heron Therapeutics
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
- Five stocks we like better than Heron Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What are earnings reports?
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- ETF Screener: Uses and Step-by-Step Guide
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.